Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
giovedì, ottobre 22
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Rhythm Pharmaceuticals Inc
RYTM
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$89.44
0.82
0.93%
Ult. Agg.: Oct 22, 3:28 PM
$87.90
-0.72
-0.81%
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Privacy Manager
Utili:
I risultati di Q3 2026 tra 12 giorni da adesso in mar nov 3rd, prima dell'apertura del mercato
Rhythm Pharmaceuticals Financials
Rhythm Pharmaceuticals (RYTM) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Rhythm Pharmaceuticals Q2 EPS $(0.73) Beats $(0.82) Estimate, Sales $71.255M Beat $67.277M Estimate
Rhythm Pharmaceuticals (NASDAQ:RYTM) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.82) by 10.98 percent. This is a 2.67 percent increase over losses of $(0.75) per share
Benzinga Newsdesk
Rhythm Pharmaceuticals Analysts Boost Their Forecasts Following Upbeat Q1 Results
Rhythm Pharmaceuticals (NASDAQ: RYTM) reported better-than-expected earnings, with strong demand for IMCIVREE and potential launches in Europe and Japan.
Avi Kapoor
Earnings Scheduled For May 5, 2026
Benzinga Insights
PRO
Rhythm Pharmaceuticals Anticipates Approximately $385M-$415M In Non-GAAP Operating Expenses In Fiscal 2026
Benzinga Newsdesk
PRO
Rhythm Pharmaceuticals Q1 EPS $(0.83) Beats $(0.84) Estimate, Sales $60.112M Beat $55.776M Estimate
Benzinga Newsdesk
Stock Market Today: Dow, S&P 500 Futures Tick Up As Oil Prices Rise, US Allies Reject Trump's Hormuz Call— Uber, Lululemon, Cisco In Focus (UPDATED)
(Editor’s note: The future prices of benchmark tracking ETFs, the lede, and the headline were updated in the story.) Dow Jones and S&P 500 futures pared earlier losses to trade slightly up on Tuesday, while Nasdaq futures were trading lower following Monday’s gains. Futures of the major benchmark indices were mixed.
Rishabh Mishra
